Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease
Background: The inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC) is a complex disease with multifactorial etiology. The intestinal dysbiosis have been investigated to play an important role in IBD pathogenesis and disease activity. The aim of our stu...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Journal of Microbiology, Immunology and Infection |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1684118224001841 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087870750326784 |
|---|---|
| author | Yu-Chieh Tsai Wei-Chen Tai Chih-Ming Liang Cheng-Kun Wu Ming-Chao Tsai Wan-Hsiang Hu Pao-Yuan Huang Chien-Hung Chen Yuan-Hung Kuo Chih-Chien Yao Seng-Kee Chuah |
| author_facet | Yu-Chieh Tsai Wei-Chen Tai Chih-Ming Liang Cheng-Kun Wu Ming-Chao Tsai Wan-Hsiang Hu Pao-Yuan Huang Chien-Hung Chen Yuan-Hung Kuo Chih-Chien Yao Seng-Kee Chuah |
| author_sort | Yu-Chieh Tsai |
| collection | DOAJ |
| description | Background: The inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC) is a complex disease with multifactorial etiology. The intestinal dysbiosis have been investigated to play an important role in IBD pathogenesis and disease activity. The aim of our study was to analyze the intestinal microbiota composition in IBD across different severity levels and the impact of biologic therapy on microbiota modulation. Methods: In this study, 27 IBD patients were recruited, including 14 patients undergoing biologic therapy for moderate to severe disease activity and 13 controls with inactive disease. The gut microbial composition was determined by 16 S ribosomal RNA gene sequencing of stool samples. Results: Biologic therapy led to significant clinical improvement in IBD disease activity after 48 weeks. About species richness, community alpha diversity was significant lower in active CD patients and enriched gradually after biologic therapy. The beta-diversity regard to the difference of bacterial community composition showed significant difference between patients in biologic and control group. A decrease in Firmicutes and increase in Bacteroidetes abundance were observed in patients with active disease, both in CD and UC. Biologic treatment induced shifts in gut microbiota, with increased Firmicutes and decreased Bacteroidetes, as well as improved F/B ratio gradually after treatment, correlating with disease activity. Conclusions: Our study suggested that gut microbiota differences changed after biologic therapies among IBD with different disease activity, and a rising Firmicutes/Bacteroidetes ratio could be a potential predictor for disease activity and treatment response monitoring. |
| format | Article |
| id | doaj-art-ee47e57800c14ab2889f165cfe6e45fd |
| institution | Kabale University |
| issn | 1684-1182 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Microbiology, Immunology and Infection |
| spelling | doaj-art-ee47e57800c14ab2889f165cfe6e45fd2025-02-06T05:11:19ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822025-02-015816269Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel diseaseYu-Chieh Tsai0Wei-Chen Tai1Chih-Ming Liang2Cheng-Kun Wu3Ming-Chao Tsai4Wan-Hsiang Hu5Pao-Yuan Huang6Chien-Hung Chen7Yuan-Hung Kuo8Chih-Chien Yao9Seng-Kee Chuah10Diversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, Taiwan; Corresponding author. Diversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.Diversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanDivision of Colorectal Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanDiversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, Taiwan; Corresponding author. Diversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.Diversion of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Chang Gung University College of Medicine, Taoyuan City, TaiwanBackground: The inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC) is a complex disease with multifactorial etiology. The intestinal dysbiosis have been investigated to play an important role in IBD pathogenesis and disease activity. The aim of our study was to analyze the intestinal microbiota composition in IBD across different severity levels and the impact of biologic therapy on microbiota modulation. Methods: In this study, 27 IBD patients were recruited, including 14 patients undergoing biologic therapy for moderate to severe disease activity and 13 controls with inactive disease. The gut microbial composition was determined by 16 S ribosomal RNA gene sequencing of stool samples. Results: Biologic therapy led to significant clinical improvement in IBD disease activity after 48 weeks. About species richness, community alpha diversity was significant lower in active CD patients and enriched gradually after biologic therapy. The beta-diversity regard to the difference of bacterial community composition showed significant difference between patients in biologic and control group. A decrease in Firmicutes and increase in Bacteroidetes abundance were observed in patients with active disease, both in CD and UC. Biologic treatment induced shifts in gut microbiota, with increased Firmicutes and decreased Bacteroidetes, as well as improved F/B ratio gradually after treatment, correlating with disease activity. Conclusions: Our study suggested that gut microbiota differences changed after biologic therapies among IBD with different disease activity, and a rising Firmicutes/Bacteroidetes ratio could be a potential predictor for disease activity and treatment response monitoring.http://www.sciencedirect.com/science/article/pii/S1684118224001841Inflammatory bowel diseaseBiologicsGut microbiotaFirmicutes/bacteroidetes ratio |
| spellingShingle | Yu-Chieh Tsai Wei-Chen Tai Chih-Ming Liang Cheng-Kun Wu Ming-Chao Tsai Wan-Hsiang Hu Pao-Yuan Huang Chien-Hung Chen Yuan-Hung Kuo Chih-Chien Yao Seng-Kee Chuah Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease Journal of Microbiology, Immunology and Infection Inflammatory bowel disease Biologics Gut microbiota Firmicutes/bacteroidetes ratio |
| title | Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease |
| title_full | Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease |
| title_fullStr | Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease |
| title_full_unstemmed | Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease |
| title_short | Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease |
| title_sort | alternations of the gut microbiota and the firmicutes bacteroidetes ratio after biologic treatment in inflammatory bowel disease |
| topic | Inflammatory bowel disease Biologics Gut microbiota Firmicutes/bacteroidetes ratio |
| url | http://www.sciencedirect.com/science/article/pii/S1684118224001841 |
| work_keys_str_mv | AT yuchiehtsai alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT weichentai alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT chihmingliang alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT chengkunwu alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT mingchaotsai alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT wanhsianghu alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT paoyuanhuang alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT chienhungchen alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT yuanhungkuo alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT chihchienyao alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease AT sengkeechuah alternationsofthegutmicrobiotaandthefirmicutesbacteroidetesratioafterbiologictreatmentininflammatoryboweldisease |